In last trading session, Passage Bio Inc (NASDAQ:PASG) saw 0.43 million shares changing hands with its beta currently measuring 1.19. Company’s recent per share price level of $0.68 trading at $0.04 or 6.88% at ring of the bell on the day assigns it a market valuation of $42.25M. That closing price of PASG’s stock is at a discount of -163.24% from its 52-week high price of $1.79 and is indicating a premium of 14.71% from its 52-week low price of $0.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.27 million shares which gives us an average trading volume of 267.79K if we extend that period to 3-months.
For Passage Bio Inc (PASG), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.23 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Passage Bio Inc (NASDAQ:PASG) trade information
Upright in the green during last session for gaining 6.88%, in the last five days PASG remained trading in the green while hitting it’s week-highest on Monday, 09/23/24 when the stock touched $0.68 price level, adding 6.85% to its value on the day. Passage Bio Inc’s shares saw a change of -32.28% in year-to-date performance and have moved 0.44% in past 5-day. Passage Bio Inc (NASDAQ:PASG) showed a performance of -3.66% in past 30-days. Number of shares sold short was 1.79 million shares which calculate 7.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 88.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -782.35% in reaching the projected high whereas dropping to the targeted low would mean a loss of -782.35% for stock’s current value.
Passage Bio Inc (PASG) estimates and forecasts
Statistics highlight that Passage Bio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -49.33% of value to its shares in past 6 months, showing an annual growth rate of 49.46% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.33M for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.23% during past 5 years.
Passage Bio Inc (NASDAQ:PASG)’s Major holders
Insiders are in possession of 0.49% of company’s total shares while institution are holding 60.57 percent of that, with stock having share float percentage of 60.87%. Investors also watch the number of corporate investors in a company very closely, which is 60.57% institutions for Passage Bio Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at PASG for having 10.12 million shares of worth $8.04 million. And as of 2024-06-30, it was holding 17.9847 of the company’s outstanding shares.
The second largest institutional holder is VESTAL POINT CAPITAL, LP, which was holding about 6.05 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.7504 of outstanding shares, having a total worth of $4.81 million.
